Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10157-022-02286-x | DOI Listing |
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9813018 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Concentration-QT modeling demonstrates that the selective mineralocorticoid receptor modulator, balcinrenone (AZD9977), does not prolong QT interval.
CPT Pharmacometrics Syst Pharmacol
November 2024
Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Article Synopsis
- Balcinrenone (AZD9977) is a selective mineralocorticoid receptor modulator being tested for heart failure treatment alongside dapagliflozin, particularly for patients with impaired kidney function.
- A study involving 62 healthy male participants evaluated various oral doses of balcinrenone to assess its impact on the QT interval using electrocardiograms and plasma concentration measurements.
- The analysis suggested that balcinrenone does not significantly prolong the QT interval, even at high therapeutic doses, remaining below the regulatory concern threshold.
Correction: Balleza Alejandri et al. Empagliflozin and Dapagliflozin Improve Endothelial Function in Mexican Patients with Type 2 Diabetes Mellitus: A Double-Blind Clinical Trial. 2024, , 182.
J Cardiovasc Dev Dis
October 2024
Department of Physiology, University Health Sciences Center, Universidad de Guadalajara, Guadalajara 44340, Mexico.
In the original publication [...
View Article and Find Full Text PDFCorrection: Ng et al. Effect of Dapagliflozin and Magnesium Supplementation on Renal Magnesium Handling and Magnesium Homeostasis in Metabolic Syndrome. 2021, 4088.
Nutrients
October 2024
Division of Nephrology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung 83301, Taiwan.
In the original publication [...
View Article and Find Full Text PDFOutcomes of Pediatric Liver Transplantation in Glycogen Storage Disease Type 1b-A Single-Center Experience.
Pediatr Transplant
November 2024
Liver Unit (Including Small Bowel Transplantation), Birmingham Children's Hospital, Birmingham, UK.
Article Synopsis
- Liver transplantation (LT) for children with glycogen storage disease type 1b can reduce infection-related hospital visits but does not improve neutropenia or the need for granulocyte colony-stimulating factor (G-CSF) post-transplant.
- In a study of eight children, most showed signs of graft rejection despite adequate immunosuppression, and while body mass index (BMI) significantly decreased, height remained unchanged after LT.
- The use of dapagliflozin helped stop G-CSF administration and led to lower gastrointestinal and infection-related issues, but did not enhance neutrophil counts.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!